We have located links that may give you full text access.
Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas.
Blood 2023 December 26
Despite newer targeted therapies, patients with primary refractory or relapsed (r/r) T-cell lymphoma have a poor prognosis. Development of CAR-T cell platforms to treat T-cell malignancies often requires additional gene modification to overcome fratricide due to shared T-cell antigens on normal and malignant T-cells. We developed a CD5-directed CAR that produces minimal fratricide by downmodulating CD5 protein levels on transduced T-cells while retaining strong cytotoxicity against CD5 positive malignant cells. In our first-in-human phase 1 study (NCT0308190), second-generation autologous CD5.CAR T-cells were manufactured from patients with r/r T-cell malignancies. Here we report safety and efficacy data from the cohort of patients with mature T-cell lymphoma (TCL). Among the 17 TCL patients enrolled, CD5 CAR-T cells were successfully manufactured for 13 out of 14 attempted line (93%) and administered to 9 (69%) patients. The overall response rate (complete remission or partial response) was 44% with complete responses observed in 2 patients. Another patient successfully proceeded to hematopoietic stem cell transplantation (HSCT) following a second infusion after an initial mixed response. The most common grade 3 or higher adverse events were cytopenias: neutropenia (100%), lymphopenia (100%), thrombocytopenia (78%), and anemia (89%). No grade 3 or higher cytokine release syndrome or neurologic events occurred. Two patients died during the immediate toxicity evaluation period due to rapidly progressive disease. These results demonstrate that CD5.CAR-T cells are safe and can induce clinical responses patients with r/r CD5-expressing TCLs without eliminating endogenous T-cells or increasing infectious complications. More patients and longer follow-up are needed for validation. NCT0308190.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app